HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Featuring an interview with Dr Erika Hamilton, including the following topics:
- General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
- Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11)
- Mechanisms of resistance to endocrine therapy (10:08)
- Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26)
- Other applications for PROTACs (24:24)
- Emerging data from the Phase III evERA trial (27:38)
- Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51)
CME information and select publications
Pas encore de commentaire